Drain-Less Abdominally Based Breast Reconstruction Using Lysine-Derived Urethane Adhesive

Sponsor
Case Comprehensive Cancer Center (Other)
Overall Status
Withdrawn
CT.gov ID
NCT03159598
Collaborator
(none)
0
3
10

Study Details

Study Description

Brief Summary

Drains are routinely utilized in breast reconstruction when using abdominal tissue of the patient to remove fluid buildup while the body heals after surgery. However, drains are associated with patient discomfort, anxiety, decreased mobility, increased hospital stays and outpatient visits. Drains can also serve as a site of origin for infection as the system is not completely closed, and infectious organisms could theoretically use the drain as point of entry.

This proposed study investigates a potential novel mechanism to prevent the development of seromas (pockets of clear fluid which can develop after surgery) in patients who undergo breast reconstruction with their own abdominal tissue. By eliminating the required use of a drain, the study team expects patients to have less pain and use less pain medication, as well as more satisfaction with their overall surgical experience.

Condition or Disease Intervention/Treatment Phase
  • Device: Tissue Glu
  • Device: Drain
  • Other: Questionnaires
N/A

Detailed Description

Objectives:
  1. Establish the safety of a lysine-derived urethane adhesive (TissuGlu, Cohera Medical) in patients undergoing autologous abdominal-based breast reconstruction. This will be assessed via analyzing complication profiles of patients post-operatively. The primary endpoints are rate of seroma development, need for seroma drainage and time to drain removal (if in drain group).

  2. Determine if there is a difference in pain and other quality of life measures when comparing patients who do and do not have abdominal drains. This will be assessed via pain medicine utilization and by delivering a targeted survey pre-operatively, as well as at post-operative day three and four weeks.

Study Design:

Patients will be randomized to one of three arms: 1) Traditional closed-suction drains, 2) TissuGlu with closed-suction drains and 3) TissuGlu without closed-suction drains.

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
This study has three parallel groups. One experimental and two control groupsThis study has three parallel groups. One experimental and two control groups
Masking:
Single (Participant)
Masking Description:
The study is "semi-blind" in that patients will not be told which treatment they are receiving. If the patient is assigned to one of the drains groups, she will know post-operatively that she has drains, but she will not know if TissueGlu was utilized. The doctor will be aware of what treatment the patient is receiving, as he or she will administer the drug
Primary Purpose:
Supportive Care
Official Title:
Drain-Less Abdominally Based Breast Reconstruction Using a Novel Lysine-Derived Urethane Adhesive (TissueGlu, Cohera Medical)
Anticipated Study Start Date :
Nov 1, 2020
Anticipated Primary Completion Date :
Feb 1, 2021
Anticipated Study Completion Date :
Sep 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Tissue Glu with drains

This is standard of care to use Tissue Glu in addition to a drain. Pre-operatively, as well as on post-operative patients will be asked to complete a questionnaire that addresses their pain, impact of drains on activities of daily living, social and physical activities. Patients will also be asked to provide information regarding who is caring for the drains, the impact of drains on the caregiver, the amount of anxiety the patient has related to drain removal and the amount of pain associated with drain removal

Device: Tissue Glu
Once adequate hemostasis has been achieved during surgery and the abdominal fascia and flaps have been irrigated, Tissue Glu will be applied. Tissue Glu is applied at approximately one centimeter intervals while remaining one centimeter away from the umbilicus and inferior incisions.
Other Names:
  • TissuGlu
  • lysine-derived urethane adhesive
  • Device: Drain
    Drains will be placed during surgery to allow for the drainage of seroma which may develop after surgery
    Other Names:
  • closed-suction drains
  • Other: Questionnaires
    Questionnaires given to patients pre-and post surgery to determine pain, impact of breast reconstruction on activity, and impact of breast reconstruction on caregivers

    Experimental: Tissue Glu without drains

    This group utilizes Tissue Glu without the presence of a drain. Pre-operatively, as well as on post-operative patients will be asked to complete a questionnaire that addresses their pain, impact of drains on activities of daily living, social and physical activities. Patients will also be asked to provide information regarding who is caring for the drains, the impact of drains on the caregiver, the amount of anxiety the patient has related to drain removal and the amount of pain associated with drain removal

    Device: Tissue Glu
    Once adequate hemostasis has been achieved during surgery and the abdominal fascia and flaps have been irrigated, Tissue Glu will be applied. Tissue Glu is applied at approximately one centimeter intervals while remaining one centimeter away from the umbilicus and inferior incisions.
    Other Names:
  • TissuGlu
  • lysine-derived urethane adhesive
  • Other: Questionnaires
    Questionnaires given to patients pre-and post surgery to determine pain, impact of breast reconstruction on activity, and impact of breast reconstruction on caregivers

    Active Comparator: Drains

    This is standard of care to use traditional closed-suction drains. Pre-operatively, as well as on post-operative patients will be asked to complete a questionnaire that addresses their pain, impact of drains on activities of daily living, social and physical activities. Patients will also be asked to provide information regarding who is caring for the drains, the impact of drains on the caregiver, the amount of anxiety the patient has related to drain removal and the amount of pain associated with drain removal

    Device: Drain
    Drains will be placed during surgery to allow for the drainage of seroma which may develop after surgery
    Other Names:
  • closed-suction drains
  • Other: Questionnaires
    Questionnaires given to patients pre-and post surgery to determine pain, impact of breast reconstruction on activity, and impact of breast reconstruction on caregivers

    Outcome Measures

    Primary Outcome Measures

    1. Rate of seroma development [Up to 30 days after surgery]

      Number of seromas which develop during the first 30 days after surgery.

    Secondary Outcome Measures

    1. Difference in pain between patients with and without abdominal drains [Up to 4 weeks after surgery]

      Patients will be given a questionnaire pre-operatively and the same questionnaire post-operatively. The change in these questionnaires will be compared between groups

    2. Pain Medicine Utilization [Up to 4 weeks after surgery]

      Use of pain medicine after surgery between groups, as indicated by chart review

    3. Time to drain removal [Up to 4 weeks after surgery]

      Time from surgery to the removal of the drain for any reason, in patients who were given a drain

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    22 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients undergoing Abdominally-Based Breast Reconstruction

    • Both unilateral or bilateral reconstruction is allowed

    • Both delayed or immediate reconstruction is allowed

    Exclusion Criteria:
    • Diabetes

    • BMI>30

    • Active smokers.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Case Comprehensive Cancer Center

    Investigators

    • Principal Investigator: Andrea Moreira, MD, Cleveland Clinic, Case Comprehensive Cancer Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Case Comprehensive Cancer Center
    ClinicalTrials.gov Identifier:
    NCT03159598
    Other Study ID Numbers:
    • CASE5117
    First Posted:
    May 18, 2017
    Last Update Posted:
    Nov 24, 2020
    Last Verified:
    Nov 1, 2020
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by Case Comprehensive Cancer Center
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 24, 2020